←Back to Expert Scholars
Translational Medicine / 转化医学Head and Neck Cancer
Tanguy Seiwert
MD
🏢Johns Hopkins Sidney Kimmel Cancer Center🌐USA
Chief, Division of Head and Neck Oncology
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Tanguy Seiwert led the KEYNOTE-012 trial of pembrolizumab in head and neck cancer and has contributed substantially to PD-L1 combined positive score biomarker development. He now directs head and neck oncology at Johns Hopkins.
Share:
🧪Research Fields 研究领域
pembrolizumab HNSCC
KEYNOTE-012
HPV biomarkers
head and neck immunotherapy
CPS score
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Tanguy Seiwert 的研究动态
Follow Tanguy Seiwert's research updates
留下邮箱，当我们发布与 Tanguy Seiwert（Johns Hopkins Sidney Kimmel Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment